Dr. Reddy's Laboratories announces launch of the generic version of Nexavar in the U.S. market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Dr. Reddy's Sorafenib Tablets, USP, 200 mg, a therapeutic generic equivalent of Nexavar® (sorafenib) Tablets in the U.S. market following the approval by the U.S. Food and Drug Administration (USFDA).

"We are pleased to launch this important generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients," says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories Inc.

Dr. Reddy's Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4268.25 as compared to the previous close of Rs. 4353.00. The total number of shares traded during the day was 10040 in over 2699 trades.

The stock hit an intraday high of Rs. 4353.00 and intraday low of 4257.05. The net turnover during the day was Rs. 43199281.00.

Source : Equity Bulls

Keywords

DrReddysLaboratories INE089A01023 RDY Nexavar GenericVersion SorafenibTablets USFDAApproval